Mon, Nov 04, 2024
Analysts at Zee Business estimate that while Dr Reddy’s may face lower revenues from its US portfolio, Revlimid sales, contributing around $125 million, are likely to provide critical support.
More >
Thu, Jul 04, 2024
According to the report, Dr Reddy's Laboratories is recalling drugs to treat insomnia and gout in the American market.
Thu, Jun 27, 2024
Dr Reddy's shares price target: Jefferies has maintained an underperform rating on Dr Reddy's with a target of Rs 5,010 per share.
Sun, May 05, 2024
Brokerage Axis Securities recommends buying stocks for two weeks. These include Orient Electric, Coal India, JSW Energy among others.
Tue, Apr 23, 2024
The company is recalling affected lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level due to powder discoloration in some packets leading to decreased potency, the Hyderabad-based drug maker said in a regulatory filing.
Wed, Jul 26, 2023
Dr Reddy's Laboratories on Wednesday reported an 18 per cent increase in consolidated profit after tax at Rs 1,405 crore in the June quarter, fuelled by US generics and strong performance in Russia.
Thu, Jul 13, 2023
Dr Reddys share price NSE, Dr Reddys news USFDA: Shares of Dr Reddy's edged lower in the early morning deals after the pharma major informed the bourses on Wednesday that the biologics license application for its proposed biosimilar rituximab candidate, DRL_RI, has been accepted for review by USFDA, EMA and MHRA.
Tue, Jul 11, 2023
Dr Reddy's Laboratories is looking to enhance its presence in various emerging segments like nutraceuticals and aims to get into integrated digital healthcare services as part of its future growth plans.
Wed, May 10, 2023
PAT for the fourth quarter was Rs 996.2 crore against Rs 87.5 crore in the corresponding quarter last year. The company's revenue from operations in the quarter under review jumped 15.84 per cent, up to Rs 6,297 crore from Rs 5,436 in Q4 last year.
Tue, Apr 18, 2023
Trading ideas for April 18: In this edition of Traders' Diary, the Zee Business research team shares exclusive research on 20 stocks that investors and traders can track on Tuesday. Dr Reddy's, Havells India, Garism, Bank of Baroda, Tata Consumer and other 15 shares analysts suggest to 'buy' for good returns.
Tue, Feb 28, 2023
Brokerages are bullish on Dr Reddy's Laboratories, Bajaj Auto, and skeptical on Wipro. Here's what top brokerages recommend on some of the key stocks in focus today.
Thu, Dec 29, 2022
In a regulatory filing, the company said on December 22, 2022 and December 27, 2022, the plaintiffs voluntarily dismissed Dr Reddy's Laboratories Ltd and Dr Reddy's Laboratories, Inc. Respectively, from the case.
Mon, Oct 03, 2022
The 30-share BSE Sensex fell 638.11 points or 1.11 per cent to settle at 56,788.81. The NSE Nifty went lower by 207 points or 1.21 per cent to end at 17,887.35.
Fri, May 20, 2022
Shares of Dr Reddy's surged eight per cent amid a spurt in volume to Rs 4247 a share on Friday's intraday trade after the company came out with its earnings for the quarter ended March 31, 2022
Wed, Mar 30, 2022
Directorate General of GST Intelligence (DGGI) which works under the aegis of the Ministry of Finance has taken action against many big pharma companies in the country for not filing Goods and Services Tax (GST). The pharma giants included are Dr. Reddys Laboratories, Glenmark, Aurobindo Pharma, Mylan and Cipla, as reported by Zee Business’s Tarun Sharma.
Fri, Mar 11, 2022
Certain stocks were in action in either direction based on reports linked to them. Here is a list of some of such stocks.
Wed, Mar 02, 2022
Wed, Jan 05, 2022
On Tuesday, Dr Reddy`s Laboratories announced that Molflu, the oral anti-viral drug for treatment of COVID-19, will be priced at Rs 35 per capsule with 10 capsules contained per strip.
Wed, Dec 29, 2021
The rise of the Covid-19 variant Omicron has once again brought pharma shares in focus.
Mon, Nov 29, 2021
Dr. Reddy’ Laboratories is in talks with partners to export domestically made doses of Russia’s COVID-19 vaccine, Sputnik, after New Delhi recently approved shipments of other shots, the firm said on Monday.
Fri, Oct 29, 2021
Pharmaceutical major Dr Reddy’s Laboratories has reported healthy quarterly numbers on a year-on-year basis during the second quarter of the financial year 2021-22 (Q2FY22). Almost on all fronts, the company has reported double-digit growth during the quarter.
Tue, Oct 19, 2021
Dr. Reddy's Laboratories Ltd. has announced the final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide capsules, from the U.S. Food and Drug Administration (USFDA).
Sat, Sep 04, 2021
Dr Reddy's Laboratories on Saturday said it has inked a pact with US-based Citius Pharmaceuticals to sell its rights to an anti-cancer agent.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
